Form 4: Phreesia SVP David Linetsky Sells Shares Under 10b5-1 Trading Plan

David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 1,100 shares of common stock at $20.49 per share under a pre-arranged 10b5-1 trading plan.

Summary

• David Linetsky, SVP of Life Sciences at Phreesia, Inc., reported a transaction involving the sale of Phreesia's common stock.
• On October 18, 2024, Linetsky sold 1,100 shares at a price of $20.49 per share.
• The sale was executed under a 10b5-1 trading plan adopted on July 18, 2024.
• Following the transaction, Linetsky directly owns 200,207 shares of common stock and indirectly owns 8,971 shares through his spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports a routine stock sale under a pre-existing 10b5-1 trading plan, which doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider selling can be interpreted in various ways by the market. While routine sales under 10b5-1 plans are common, investors often scrutinize such transactions for insights into management's perspective on the company's valuation and future prospects. It's important to consider the size of the sale relative to the individual's holdings and the overall trading volume of the stock.

Comparison to Industry Standards

• Comparing Linetsky's trading activity to other executives in similar healthcare technology companies could provide context.
• For example, if executives at Veeva Systems (VEEV) or athenahealth have similar trading patterns under 10b5-1 plans, it might suggest a standard practice within the industry.
• However, if Linetsky's selling activity is significantly higher than peers, it could raise concerns.

Stakeholder Impact

• The sale of shares by an executive could create uncertainty among shareholders, although the impact is likely to be minimal given the existence of a 10b5-1 trading plan.

Key Dates